article
Spatial biology is the next life science revolution
Dr Richard Goodwin, Head of Imaging & AI, Clinical Pharmacology & Safety Sciences at AstraZeneca, explores the latest innovation in early therapeutic development – spatial biology.
List view / Grid view
Informatics
news
Molecular Devices launches automated workcells for ELISA workflows
Showcasing select automated instruments and capabilities at Society for Laboratory Automation and Screening Europe 2022 Conference and Exhibition in Dublin, Ireland.
news
Novel process revolutionises microfluidic fabrication
Researchers have implemented structural colour printing in microfluidic fabrication which creates new pathways for medical diagnostics and miniaturised sensors.
news
Novel machine learning technique to develop new drugs
New machine learning models could propose new molecules that have specific properties which could fight certain diseases, doing in minutes what might take humans months to achieve manually.
news
Grant awarded to research centre to create lab-on-a-chip technology
A research centre based at the University of Kansas has been awarded $6.6 million to create lab-on-a-chip technology for medical tests.
news
A novel tool for studying autoimmune diseases related to COVID-19
Researchers have developed a new bioinformatics pipeline that could help investigate the mechanism underlying the development of autoimmune diseases following SARS-CoV-2 infection.
news
Sartorius Launches the Octet® SF3 SPR System, Strengthening its Leadership in Advanced Label-Free Bioanalytics
Sartorius has launched a proprietary fluidic-free instrument platform for real-time, label-free analysis of biomolecular interactions.
news
A revolutionary deep learning model to predict undesired drug-drug interactions
Scientists have developed a deep learning-based model trained on drug-induced gene expression signatures to predict drug-drug interactions.
news
A machine learning model that could identify antibody targets
Using a machine learning model, scientists could predict not only the virus an antibody will attack, but which features on the pathogen the antibody binds to.
podcasts
Episode 7 – Cell line development with Dr Natasa Skoko, ICGEB & Dr Hugh Graham, MacroGenics
Tune in to this podcast to hear industry experts discuss cell line monoclonality and the emerging methods that can support clonal origin assurance.
article
Emerging trends in biotherapeutic development
The COVID-19 pandemic has placed a spotlight on the discovery and development of biotherapeutics, for both the treatment and prevention of diseases. In this article, industry experts discuss the emerging trends they see in biotherapeutic development and how they predict the field will evolve in the near future.
whitepaper
Bulletin: Utilising the multiparameter capability of the Ze5 Cell Analyser to monitor T cell exhaustion and effects of immunotherapy
Read this bulletin to learn about a Bio-Rad study where they developed and tested a 16-parameter flow cytometry panel applicable to the interrogation of a range of biologically relevant markers of T cell activation.
article
Enhancing confocal microscopy with AI
Improving processes in the lab can enable researchers to spend their time on other tasks and increase the accuracy of their findings, including when imaging. In this Q&A, Dr Hari Shroff from the US National Institutes of Health (NIH) discusses his recent study, published in Nature where confocal microscopy was…
article
An equal seat at the table for AI in pharmaceutical discovery
This article explores the current state of artificial intelligence (AI) in drug discovery and development, discussing the obstacles holding back wider adoption. Dr Mark Eller, Senior Vice President of Research and Development at Aria Pharmaceuticals, makes the case that to succeed, AI must be integrated as a partner alongside core…
article
Drug Target Review – Issue 1 2022
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
